Detalles de la búsqueda
1.
Budget impact analysis of a digital monitoring platform for COPD.
Cost Eff Resour Alloc
; 21(1): 36, 2023 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37271821
2.
Decreased Opioid Utilization and Cost at One Year in Chronic Low Back Pain Patients Treated with Transcutaneous Electric Nerve Stimulation (TENS).
Surg Technol Int
; 27: 268-74, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26680409
3.
Impact of Pseudomonas aeruginosa on resource utilization and costs in patients with exacerbated non-cystic fibrosis bronchiectasis.
J Med Econ
; 27(1): 671-677, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38646702
4.
Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in Canada.
Appl Health Econ Health Policy
; 8(4): 267-80, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20578781
5.
Objective measurement in Parkinson's disease: a descriptive analysis of Parkinson's symptom scores from a large population of patients across the world using the Personal KinetiGraph®.
J Clin Mov Disord
; 7: 5, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32377368
6.
Health economic comparison between continuous subcutaneous insulin infusion and multiple daily injections of insulin for the treatment of adult type 1 diabetes in Canada.
Clin Ther
; 31(3): 657-67, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19393856
7.
A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective.
Value Health
; 12(5): 674-86, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19171006
8.
Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: a US analysis based on PROactive.
Value Health
; 12(1): 1-9, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-18657104
9.
Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus.
Value Health
; 11(1): 22-33, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-18237357
10.
The impact of clinical trial design on cost-effectiveness analyses: illustration from a published study of the one-touch ultrasmart blood glucose meter for insulin-using diabetes patients.
Diabetes Technol Ther
; 10(3): 227-31, 2008 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-18473698
11.
Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.
Appl Health Econ Health Policy
; 6(2-3): 103-12, 2008.
Artículo
en Inglés
| MEDLINE | ID: mdl-19231904
12.
Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia.
Pharmacoeconomics
; 25(10): 881-97, 2007.
Artículo
en Inglés
| MEDLINE | ID: mdl-17887808
13.
Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
J Manag Care Pharm
; 12(9): 726-35, 2006.
Artículo
en Inglés
| MEDLINE | ID: mdl-17249905
14.
Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States.
Clin Ther
; 27(6): 940-50, 2005 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-16117994
15.
The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making.
Curr Med Res Opin
; 20 Suppl 1: S5-26, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15324513
16.
Validation of the CORE Diabetes Model against epidemiological and clinical studies.
Curr Med Res Opin
; 20 Suppl 1: S27-40, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15324514
17.
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
Curr Med Res Opin
; 20 Suppl 1: S41-51, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15324515
18.
Impact of changes in HbA1c, lipids and blood pressure on long-term outcomes in type 2 diabetes patients: an analysis using the CORE Diabetes Model.
Curr Med Res Opin
; 20 Suppl 1: S53-8, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15324516
19.
What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE Diabetes Model.
Curr Med Res Opin
; 20 Suppl 1: S59-66, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15324517
20.
Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy.
Curr Med Res Opin
; 20 Suppl 1: S67-73, 2004 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-15324518